Kerstin Wolff of Maiwald explains how the EU’s provisional agreement on plants generated by new genomic techniques divides them into two categories, opening the market while preserving patent and regulatory oversight
Kerstin Wolff and Tobias Matschke of Maiwald Intellectual Property examine a landmark Unified Patent Court decision on second medical use claims and compare it with Germany’s established approach to ‘skinny label’ products
Kerstin Wolff of Maiwald Intellectual Property examines the EU’s winding path towards the regulation of new genomic techniques, with a proposed patent ban remaining a key source of contention
Kerstin Wolff of Maiwald reports on a proposal that supports the use of some plants generated by new genomic techniques but opposes patents for all plants obtained by such means
